Recent Posts
- HealthInvest Returns for 2026: Meet the Companies Shaping Australian Life Sciences
- Lifesaving Capital: How impact investing is shaping the future of biotech
- Investor Relations: the quiet advantage powering ASX microcaps
- HealthInvest Sydney: Life Sciences in the Investor Spotlight
- HealthInvest September 2025
Archives
Servatus launches new trial into the effects of live biotherapeutics on insomnia
Servatus launches new trial into the effects of live biotherapeutics on insomnia, we talk to CEO Dr Wayne Finlayson to discuss this exciting initiative.
Servatus CEO Dr Wayne Finlayson discusses the company’s new human clinical trial into the link between the gut microbiome and sleep by treating patients who suffer from insomnia with live biotherapeutics
